Featured in:
July, September, November, and December editions

• Are multispecific and dual-payload formats solving real clinical problems, or adding complexity ahead of the evidence?
• The expanding definition of “bioconjugate” where ADCs end, and a broader modality class begins
• What the field can and cannot carry over from ADCs as it moves into oligonucleotides, peptides, and radioconjugates
• The strategic case for diversifying beyond oncology: clinical opportunity versus development risk
• How novel formats reshape expectations for manufacturing, analytics, and regulatory pathways
• Which next-generation formats are most likely to reach regulatory approval and move into the clinic
• Partnership and platform models driving emerging-modality programs

Featured in:
August, October, November, and December editions 

• The manufacturing readiness gap
  • Why promising conjugates stall between discovery and scalable production
• Geopolitics and supply-chain strategy to de-risk access to payloads, linkers, and antibodies
• In-house vs CDMO, and how the outsourcing landscape is shaping manufacturing decisions
• Designing manufacturing for a pipeline of increasingly diverse and complex formats
• Cost of goods as a strategic lever for ADC commercial viability and patient access
• What ADC scale-up has taught the industry, and how transferable those lessons are to new modalities
• Building flexibility through platform facilities and processes for a multi-modality future

Featured in:
September and November editions

• Standardization and harmonization of methods across the field and with regulators
• Connecting analytical attributes to clinical meaning to assess which CQAs actually predict outcomes
• The shift from release testing toward deeper structural and functional understanding
• Analytical strategies for a multi-modality pipeline beyond traditional ADCs
• Where automation, high-throughput, and informatics genuinely pay off
• Data and AI in conjugate characterization
• Analytics as the bottleneck – is characterization keeping pace with conjugate complexity?

Featured in:
August and October editions

• Why ADCs fail in translation, and what would meaningfully improve preclinical predictivity
• Designing the preclinical package backward from the clinical and regulatory question
• The model problem: Do current in vitro and animal systems truly reflect human conjugate behavior?
• Integrating PK/PD, biodistribution, and safety into a single translational story
• How much preclinical evidence is “enough” to justify first-in-human, and who decides
• Translational lessons being read across from the approved ADC clinical experience
• Biomarker-led translation to build patient-selection strategy from the start

Featured in:
September and November editions

• The therapeutic-index problem as the central constraint on ADC progress, and how the field is responding
• How regulatory frameworks are adapting (or failing to adapt) to increasingly complex conjugate formats
• Designing for safety from day one versus managing toxicity in the clinic
  • Understanding and getting ahead of recurring class toxicities such as ILD, ocular, and peripheral neurotoxicity
• Class effects versus molecule-specific risks
  • What generalizes across payloads and what does not
• Regulation as a standalone theme versus embedded across design, CMC, and clinical decisions
• Building a joined-up regulatory and safety strategy from first-in-human through commercial lifecycle
• Global divergence and convergence: navigating IND, comparability, and multi-region submissions
• Can better preclinical and biomarker tools move safety understanding upstream of the clinic?

Featured in:
August, October, and December editions

• A periodic state-of-the-field read on ADC approvals, readouts, and pipeline momentum
• Why do ADCs succeed or fail in the clinic, and what separates the winners?
• Sequencing and combinations: positioning ADCs within evolving standards of care
• Designing smarter ADC trials through endpoints, patient selection, and adaptive approaches
• Translating clinical experience back into molecular and program design
• Real-world evidence and post-approval learning across the ADC class
• The clinical case for moving conjugates beyond oncology